Case study: Enhancing Pulmonary Drug Delivery in COPD Patients at Nebula Pharma

Thesis Abstract

This study investigates how Nebula Pharma can enhance pulmonary drug delivery for patients with chronic obstructive pulmonary disease (COPD) through a case-focused evaluation of formulation optimization, device compatibility, and patient-centered adherence strategies within a pharmaceutical manufacturing and clinical deployment setting. The central problem addressed is suboptimal lung deposition and variable patient adherence leading to reduced therapeutic efficacy and increased exacerbation risk. The aim is to identify actionable interventions that improve aerosolized corticosteroid and bronchodilator delivery, deposition efficiency, and real-world adherence, thereby enhancing disease control and quality of life for COPD patients. Specific objectives include (1) to quantify inhaled drug deposition patterns across Nebula Pharma’s dry powder inhaler (DPI) configurations using in vitro cascade impactor tests and in vivo gamma scintigraphy in a subset of 40 COPD patients; (2) to evaluate the impact of formulation parameters (particle size distribution, excipient composition) on pulmonary deposition via a factorial design experiment (n=200 formulation trials); (3) to examine patient-related determinants of adherence and inhaler technique using a mixed-methods approach, incorporating structured interviews (n=25) and validated adherence scales in the broader cohort (n=300); (4) to model dose-response and tolerance development using nonlinear mixed-effects modeling and time-to-event analyses for exacerbation risk; and (5) to develop a comprehensive optimization framework integrating formulation, device design, and behavior change strategies grounded in the Health Belief Model and COM-B theory. The methodological approach combines a convergent parallel mixed-methods design with robust statistical analyses. The population comprises adults diagnosed with moderate to severe COPD under Nebula Pharma-focused clinical management, with a stratified random sample of 300 patients for quantitative data and 25 patients for qualitative insights. Data collection instruments include high-resolution cascade impactor measurements for aerodynamic particle sizing, gamma scintigraphy for regional lung deposition, high-performance liquid chromatography (HPLC) for drug content, standardized inhaler technique checklists, the COPD Assessment Test (CAT), the St. George’s Respiratory Questionnaire (SGRQ), and the 8-item Morisky Medication Adherence Scale. Validity and reliability are ensured through pilot testing of instruments, inter-rater reliability assessments for technique evaluation (Cohen’s kappa >0.80), and instrument triangulation. Data analysis employs multiple regression to relate deposition metrics to formulation variables, ANOVA to compare device configurations, nonlinear mixed-effects modeling to estimate pharmacokinetic–pharmacodynamic relationships, and time-to-first-exacerbation analyses using Cox proportional hazards models. The qualitative data will be analyzed using thematic analysis to identify barriers and facilitators of proper inhaler use, with findings integrated through joint display analysis to inform the optimization framework. Ethical considerations include obtaining informed consent, ensuring patient confidentiality, and adherence to institutional review board protocols. Anticipated findings indicate that optimized particle size (1.5–2.5 ?m) with a hygroscopic excipient matrix enhances deep lung deposition, improved device-resident plume characteristics reduce regional deposition variability, and targeted patient education coupled with adherence monitoring improves correct inhaler technique by at least 25% and reduces annualized exacerbations by 15–20% in the high-risk subgroup. The study is expected to reveal significant associations between technique accuracy, adherence scores, and clinical outcomes, with the COM-B framework and Health Belief Model providing explanatory power for behavior-related determinants. The contribution to knowledge includes a validated, context-specific optimization framework linking formulation science, device engineering, and patient behavior to maximize pulmonary drug delivery in COPD within a real-world pharmaceutical setting. Practical implications encompass guidelines for iterative formulation-device testing, standardized inhaler technique training protocols, and integrated adherence-support systems in Nebula Pharma’s therapeutic programs. The main conclusion anticipates that a synergistic optimization of particle engineering, inhaler design, and patient-centered behavioral interventions yields meaningful improvements in drug delivery efficiency and clinical outcomes. Recommendations focus on implementing the optimization framework across Nebula Pharma’s product pipeline, expanding real-world evidence generation through post-marketing surveillance, and pursuing adaptive clinical trials to continually refine device-formulation combinations in response to patient and disease dynamics.